Author

Hai-Yan Xu

h-index 16 View on Semantic Scholar

We have 3 of 87 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report

For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistance and disease progression are inevitable. Identification of resistance mechanisms is crucial for guiding subsequent anti-tumor therapy. We...

Qing-Long Jiang, Rui Sun, Hai-Yan Xu et al. · Current Oncology · 0 citations

Open access Sep 2026

Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report

Small cell transformation (SCT) is a known acquired resistance mechanism to targeted therapies in non-small cell lung cancer (NSCLC) but has not been reported following HER2 tyrosine kinase inhibitor (TKI) therapy. We report the first case of SCT detected during acquired resistance to zongertinib, a novel selective...

D. Zheng, Hai-Yan Xu, Yan Wang · Frontiers in Oncology · 0 citations

Review Open access Aug 2026

Circulating tumor DNA dynamics and mutational profiles as indicators in neoadjuvant chemoimmunotherapy for resectable or borderline resectable non-small cell lung cancer

Longitudinal ctDNA assessment identified high-risk subgroups in neoadjuvant NSCLC, particularly by refining prognosis in heterogeneous SD populations, and an exploratory gene-based mutational signature provided potential molecular risk stratification.

Wenxin Jiang, Si-Yu Lei, Sijie Liu et al. · Respiratory Research · 0 citations